Dario Names Veteran Healthcare Executive John R. Palumbo Chairman of the Board as Company Positions Itself to Lead the Convergence of Consumer and Payer-Funded Care

Mr. Palumbo to join Dario's third quarter 2026 earnings call to share the Board's view on the convergence of consumer and payer-led healthcare and chronic care management

NEW YORK, Nov. 4, 2026 — DarioHealth Corp. (NASDAQ: DRIO) (the "Company", "DarioHealth" or "Dario"), a leading AI-powered healthcare technology company transforming the management of chronic conditions, today announced that its Board of Directors (the "Board") has appointed John R. Palumbo as Chairman of the Board, effective November 3, 2026. Mr. Palumbo, who joined the Board in April 2026, succeeds Yoav Shaked, who has served as Chairman since 2018 and will continue to serve as a director.

The appointment comes as two historically separate healthcare markets converge. Consumers increasingly choose their own entry point into healthcare, through AI tools, home testing and direct access to branded men's and women's health therapies, while payers continue to fund the management of underlying chronic conditions, which account for roughly 90% of U.S. health spending. Payers are redesigning plan structures, and the Centers for Medicare and Medicaid Services ("CMS"), through its ACCESS Model launched in July 2026, now pays for outcomes in hypertension, diabetes, musculoskeletal conditions and depression – conditions that align with Dario's existing chronic care management offerings.

"For a decade, the industry treated consumer health and chronic care as two different businesses. They are becoming one, and Dario has spent that decade building the platform that sits where they meet," stated Dario's Chief Executive Officer, Erez Raphael. "John has spent his career inside the payer, provider and health services organizations that are shaping where this market is going, and he has worked hand-in-hand with our team since April. Having him lead our Board as we seek to capture this opportunity is a clear statement of our ambition."

"The consumer picks the door. The payer pays for the chronic condition behind it. I believe the value moves to whomever owns the path between the two and provides a bridge for the patient," said Mr. Palumbo. "Working alongside Erez and the team over the past six months, I have seen what the market may not yet fully appreciate: a strong team, a mission-driven culture focused on members and outcomes, and a platform built for exactly that path, with consumer engagement and payer-grade evidence integrated within a single platform. As Chairman, my focus is to make sure the Company captures the full strategic value of that position."

"It has been a privilege to chair Dario since 2018," said Mr. Shaked. "John is the right leader for the Board's next chapter, and I look forward to continuing to support the Company as a director."

Dario believes this convergence will shift chronic care management from single-condition apps to an AI-led, clinician-backed and reimbursable system, with one member record reachable from either the consumer door or the payer door. Dario has spent more than a decade building that system:

• One platform, combining DarioIQ intelligence with Dario Care clinical services, with one clinical engine and one evidence base across conditions. More than 80% of Dario's contracted and late-stage annual recurring revenue ("ARR") is multi-condition.
• A proprietary stack, including FDA-cleared connected devices in members' homes and more than 13 billion proprietary data points.
• Experience on both sides of the market: consumer roots; more than 100 scientific studies; more than 180 signed enterprise accounts, including serving more than a dozen health plans.
• Published clinical and economic evidence, including $5,077 in annual savings per user and 23.5% fewer inpatient discharges among members with type 2 diabetes, and an independent Aon review of 17 studies supporting a 2.5% to 7.2% in-year reduction in total healthcare costs.
• A partner-led growth model, with approximately 75% of new accounts coming through channel partners.

Mr. Palumbo will join Dario's third quarter 2026 earnings conference call on November 12, 2026, to share the Board's perspective on these market shifts and the Company's strategic priorities.

Mr. Palumbo brings more than 40 years of healthcare operating experience across early-stage ventures and Fortune 100 enterprises. His background includes senior leadership roles at AmerisourceBergen Corporation (now Cencora, Inc.), where he led the provider business unit and expanded consulting and technology capabilities into a multibillion-dollar platform serving health systems nationwide, as well as serving as Chief Operating Officer of Allscripts Healthcare Solutions, Inc. (now Veradigm, Inc.) and holding leadership positions at Shared Medical Systems Corporation (now Oracle). He has supported two companies through IPOs and led large-scale operational and commercial transformations.

He currently serves on the boards of PM Pediatrics Management Group, LLC, Lucid Diagnostics Inc., ivWatch, LLC and Qless, Inc., and chairs the advisory board of Brado Cuneo Nollau, LLC, an AI-driven engagement platform serving health systems.

Cautionary Note Regarding Forward-Looking Statements

This news release and the statements of representatives and partners of DarioHealth Corp. related thereto contain or may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Statements that are not statements of historical fact may be deemed to be forward-looking statements. For example, the Company is using forward-looking statements in this press release when it discusses its expectations regarding the convergence of consumer-directed and payer-funded healthcare; anticipated changes in healthcare delivery, reimbursement and chronic care management models, including the potential implications of the CMS ACCESS Model; the Company's ability to capitalize on these market developments and its positioning within the evolving healthcare market; the anticipated strategic benefits of Mr. Palumbo's appointment as Chairman of the Board and his expected contributions to the Company's strategic direction, commercial development and growth initiatives; the Company's expectations regarding the continued development, integration, adoption and scalability of its AI-powered chronic care management platform; the potential clinical, operational and economic benefits of the Company's solutions, including potential improvements in patient outcomes and reductions in healthcare costs; the Company's ability to expand its relationships with health plans, employers, health systems, government entities and channel partners; and the Company's future business strategy, growth opportunities, market positioning and commercial performance. Without limiting the generality of the foregoing, words such as "plan," "project," "potential," "seek," "may," "will," "expect," "believe," "anticipate," "intend," "could," "estimate" or "continue" are intended to identify forward-looking statements. Readers are cautioned that certain important factors may affect the Company's actual results and could cause such results to differ materially from any forward-looking statements that may be made in this news release. Factors that may affect the Company's results include, but are not limited to, regulatory approvals, product demand, market acceptance, impact of competitive products and prices, product development, commercialization or technological difficulties, the success or failure of negotiations and trade, legal, social and economic risks, and the risks associated with the adequacy of existing cash resources. Additional factors that could cause or contribute to differences between the Company's actual results and forward-looking statements include, but are not limited to, those risks discussed in the Company's filings with the U.S. Securities and Exchange Commission. Readers are cautioned that actual results (including, without limitation, the timing for and results of the Company's commercial and regulatory plans for Dario™ as described herein) may differ significantly from those set forth in the forward-looking statements. The Company undertakes no obligation to publicly update any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by applicable law.

DarioHealth Corporate Contacts

Michael Lipari
SVP Corporate Development
[email protected]
+1-201-785-6310

Rob Halpern
SVP Marketing
[email protected]  

SOURCE DarioHealth Corp.